Company Overview: Global Atomic Corporation (TSX: GLO) is a diversified Canadian-based company operating through its subsidiaries, with activities spanning both the zinc recycling and uranium exploration sectors. Lineage Cell Therapeutics, Inc. (NYSE: LCTX) is a clinical-stage biotechnology company focused on the development of allogeneic (donor-derived) cell therapies aimed at treating serious neurological and ophthalmic disorders. The Report covers the Price Action, Technical Indicators Analysis along with the Stop Loss Levels, Target Prices, and Recommendations on these two stocks. 

Global Markets Wrap-Up 

As of May 1, 2025, major U.S. equity benchmarks delivered solid week-to-date (WTD) gains, driven by widespread buying across sectors. The S&P 500 advanced 1.43%, finishing the week at 5,604.14, while the NASDAQ Composite outperformed with a 1.89% gain, closing at 17,710.74, bolstered by strong momentum in the technology sector. In contrast, the Russell 2000, which tracks small-cap stocks, posted a more modest 0.93% WTD rise, ending at 1,975.86, underperforming relative to its large-cap counterparts.

In Canada, the S&P/TSX Venture Composite Index (TSX: ^JX) registered a 1.17% WTD gain, closing the week at 646.15, as of May 1. While the index continued its broader downward trend, Thursday’s session saw pockets of strength emerge in the healthcare, financials, and real estate sectors, offering some relief. However, the upside was capped by continued weakness in technology, consumer cyclicals, basic materials, industrials, energy, and consumer non-cyclicals, which weighed heavily on overall market sentiment.